Skip to main content
SpringerLink
Log in

Molecular and Functional Imaging in Oncology Therapy Response

  • Chapter
  • First Online:
Therapy Response Imaging in Oncology

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

Abstract

Molecular and functional imaging aims to assess oncologic therapy response by integrating molecular and functional tumor biology in order to assess therapeutic efficacy and improve patient outcome. Most oncologic processes reflect heterogeneous disease both functionally and morphologically. Further, clonal proliferations of cells may evolve with time becoming resistant to specific therapies. It is important to identify those cancer patients who derive benefit from therapy, such that expensive, toxic, or futile treatment is avoided in those who will not respond. The ultimate goal is to offer the right treatment to the right patient over time. Molecular and functional imaging either using positron emission tomography (PET) or gamma cameras often through hybrid scanners that also include computed tomography (CT) and/or magnetic resonance imaging (MRI) are sensitive techniques with a major role in the precision medicine algorithm of oncology patients. These modalities provide insight prior to, during, and following therapy. Further, they often serve as a biomarker of tumoral heterogeneity helping to direct the selection of appropriate treatment, and detect early response to therapy. Also, molecular and functional imaging is a powerful prognostic biomarker in oncology that can suggest patient outcome based on treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ady N, Zucker JM, Asselain B et al (1995) A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31A(2):256–261

    Article  CAS  PubMed  Google Scholar 

  • Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E (2018) FDG PET/CT for assessing tumour response to immunotherapy—report on the EANM symposium n immune modulation nd recent review of the literature. Eur J Nucl Med Mol Imaging 46:238–250

    Article  PubMed  PubMed Central  Google Scholar 

  • Aisner J, Wiernik PH (1982) Restaging laparotomy in the management of the non-Hodgkin lymphomas. Med Pediatr Oncol 10:429–438

    Article  PubMed  Google Scholar 

  • André MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1794

    Article  PubMed  Google Scholar 

  • Anwar H, Sachpekidis C, Winkler J et al (2018) Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45:376–383

    Article  CAS  PubMed  Google Scholar 

  • Barrett JA, Coleman RE, Goldsmith SJ et al (2013) First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 54:380–387

    Article  CAS  PubMed  Google Scholar 

  • Barrington SF, Qian W, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824–1833

    Article  PubMed  Google Scholar 

  • Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058

    Article  PubMed  PubMed Central  Google Scholar 

  • Beauregard JM, Hodman MS, Kong GK et al (2012) The tumor sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 39:50–56

    Article  CAS  PubMed  Google Scholar 

  • Benz MR, Herrmann K, Walter F et al (2011) 18F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 52(11):1684–1689

    Article  CAS  PubMed  Google Scholar 

  • Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354

    Article  CAS  PubMed  Google Scholar 

  • Bouchelouche K, Choyke PL, Capala J (2010) Prostate specific membrane antigen—a target for imaging and therapy with radionuclides. Discov Med 9:55–61

    PubMed  PubMed Central  Google Scholar 

  • Canellos G (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931–933

    Article  CAS  PubMed  Google Scholar 

  • Champiat S, Dercle L, Ammari S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23:1920–1928

    Article  CAS  PubMed  Google Scholar 

  • Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489–2496

    Article  CAS  PubMed  Google Scholar 

  • Cho SY, Lipson EJ, Im HJ et al (2017) Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 58:1421–1428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I (1988) Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29:1354–1359

    CAS  PubMed  Google Scholar 

  • Cook GJR, Venkitaraman R, Sohaib AS (2011) The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging 38:7–13

    Article  PubMed  Google Scholar 

  • Dennis ER, Jia X, Mezheritskiy IS et al (2012) Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30:519–524

    Article  PubMed  PubMed Central  Google Scholar 

  • Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    CAS  PubMed  Google Scholar 

  • Emmett L, Crumbaker M, Ho B et al (2018) Metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. [Epub ahead of print]

    Google Scholar 

  • Evans MJ, Smith-Jones PM, Wongvipat J et al (2011) Noninvasive measurement of androgen receptor signaling with positron emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 108:9578–9582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Even-Sapir E, Metser U, Mishani E et al (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297

    PubMed  Google Scholar 

  • Fendler W, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014–1024

    Article  PubMed  Google Scholar 

  • Furth C, Amthauer H, Hautzel H et al (2011) Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma—results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22:1198–1203

    Article  CAS  PubMed  Google Scholar 

  • Gallamini A, Fiore F, Sorasio R, Meignan M (2009) Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 50:1761–1764

    Article  PubMed  Google Scholar 

  • Gallamini A, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107–1113

    Article  PubMed  PubMed Central  Google Scholar 

  • Gerbaudo VH, Garcia CA (2016) PET/CT of lung cancer. Springer, Cham

    Book  Google Scholar 

  • van Gool MH, Aukema TS, Schaake EE et al (2014a) NEL Study Group. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer. J Nucl Med 55(7):1081–1086

    Article  PubMed  CAS  Google Scholar 

  • van Gool MH, Aukema TS, Schaake EE et al (2014b) 18F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer. Ann Surg Oncol 21(9):2831–2837

    Article  PubMed  Google Scholar 

  • Grant FD, Fahey FH, Packard AB et al (2008) Skeletal PET with 18F-fluoride: applying a new technology to an old tracer. J Nucl Med 49:68–78

    Article  PubMed  Google Scholar 

  • Hachemi M, Couturier O, Vervueren L et al (2014) [18F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS One 9(2):e87629

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hicks RJ, Mac Manus MP, Matthews JP et al (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60(2):412–418

    Article  PubMed  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoekstra CJ, Stroobants SG, Smit EF et al (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23(33):8362–8370

    Article  PubMed  Google Scholar 

  • Koerber SA, Will L, Kratochwil C et al (2018) 68Ga-PSMA-11 PET/CT in Primary and recurrent prostate carcinoma: implications for radiotherapeutic management in 121 patients. J Nucl Med [Epub ahead of print]

    Google Scholar 

  • Kostakoglu L, Schöder H, Johnson JL et al (2012) Interim FDG PET imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 53:2143–2150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35:424–437

    Article  PubMed  Google Scholar 

  • Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270–1271

    Article  PubMed  CAS  Google Scholar 

  • Lasnon C, Desmonts C, Quak E et al (2013) Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 40:985–996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lasnon C, Quak E, Le Roux PY et al (2017) EORTC response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Phys 4:17

    Article  PubMed  PubMed Central  Google Scholar 

  • Le Roux P-Y, Gastinne T, Le Gouill S et al (2011) Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 38:1064–1071

    Article  PubMed  Google Scholar 

  • Le DT, Lutz E, Uram JN et al (2013) Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:382–389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lewis E, Bernardino ME, Salvador PG, Cabanillas FF, Barnes PA, Thomas JL (1982) Post-therapy CT-detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 6:792–795

    Article  CAS  PubMed  Google Scholar 

  • Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632

    Article  PubMed  Google Scholar 

  • Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL (2005) Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49(1):95–108

    Article  PubMed  Google Scholar 

  • Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257–1260

    Article  PubMed  Google Scholar 

  • Meignan M, Gallamini A, Haioun C, Polliack A (2010) Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma 51:2171–2180

    Article  PubMed  Google Scholar 

  • Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A (2012) Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 53:1876–1881

    Article  PubMed  Google Scholar 

  • Mikhaeel N, Timothy A, Hain S, O’Doherty M (2000) 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11:S147–S150

    Article  Google Scholar 

  • Moghbel MC, Mittra E, Gallamini A et al (2017) Response assessment criteria and their applications in lymphoma: Part 2. J Nucl Med 58(1):13–22

    Article  PubMed  Google Scholar 

  • Orlandi E, Lazzarino M, Brusamolino E et al (1990) Residual mediastinal widening following therapy in Hodgkin’s disease. Hematol Oncol 8:125–131

    Article  CAS  PubMed  Google Scholar 

  • Pollen JJ, Witztum KF, Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 142:773–776

    Article  CAS  PubMed  Google Scholar 

  • Popovic A, Jaffee EM, Zaidi N (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209–3218

    Article  PubMed  PubMed Central  Google Scholar 

  • Quak E, Le Roux PY, Lasnon C et al (2016) Does PET SUV harmonization affect PERCIST response classification? J Nucl Med 57:1699–1706

    Article  CAS  PubMed  Google Scholar 

  • Reske S (2003) PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30(Suppl 1):S89–S96

    Article  PubMed  Google Scholar 

  • Reusch U, Sundaram M, Davol PA et al (2006) Anti-CD3 × anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12:183–190

    Article  CAS  PubMed  Google Scholar 

  • Rowe SP, Macura KJ, Blackford AL et al (2016) PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients wit metastatic prostate cancer. Mol Imaging Biol 18(3):411–419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saâda-Bouzid E, Defaucheux C, Karabajakian A et al (2017) Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 28:1605–1611

    Article  PubMed  Google Scholar 

  • Sachpekidis C, Anwar H, Winkler J et al (2018) The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 45:1289–1296

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402–1418

    Article  PubMed  PubMed Central  Google Scholar 

  • Schwarz SW, Decristoforo C, Goodbody AE et al (2019) Harmonization of United States, European Union and Canadian first-in-human regulatory requirements for radiopharmaceuticals—is this possible? J Nucl Med [Epub ahead of print]

    Google Scholar 

  • Sunaga N, Oriuchi N, Kaira K et al (2008) Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59(2):203–210

    Article  PubMed  Google Scholar 

  • Surbone A, Longo DL, DeVita V et al (1988) Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6:1832–1837

    Article  CAS  PubMed  Google Scholar 

  • Takahashi R, Hirata H, Tachibana I et al (2012) Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res 18(1):220–228

    Article  CAS  PubMed  Google Scholar 

  • Vansteenkiste J, Fischer BM, Dooms C, Mortensen J (2004) Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5:531–540

    Article  PubMed  Google Scholar 

  • Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S

    Article  CAS  PubMed  Google Scholar 

  • Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269–270

    CAS  PubMed  Google Scholar 

  • Warburg O, Wind F, Negelein E (1927) The metabolism of tumours in the body. J Gen Physiol 8(6):519–530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657

    Article  CAS  PubMed  Google Scholar 

  • Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420

    Article  CAS  PubMed  Google Scholar 

  • Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782

    Article  CAS  PubMed  Google Scholar 

  • Zacho HD, Petersen LJ (2018) Bone flare to androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer on 68Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 43(11):e404–e406

    Article  PubMed  Google Scholar 

  • Ziai P, Hayeri MR, Salei A et al (2016) Role of optimal quantification of FDG PET imaging in the clinical practice of radiology. Radiographics 36:481–496

    Article  PubMed  Google Scholar 

  • Zukotynski KA, Valliant J, Benard F et al (2018) Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: first observations. Clin Nucl Med 43(3):213–216

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada

    Katherine A. Zukotynski

  2. Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, AZ, USA

    Phillip H. Kuo

  3. Hanyang University College of Medicine, Seoul, South Korea

    Chun K. Kim

  4. Radiology, UT Southwestern Medical Center, Dallas, TX, USA

    Rathan M. Subramaniam

Authors
  1. Katherine A. Zukotynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip H. Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chun K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rathan M. Subramaniam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Zukotynski .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Mizuki Nishino

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zukotynski, K.A., Kuo, P.H., Kim, C.K., Subramaniam, R.M. (2020). Molecular and Functional Imaging in Oncology Therapy Response. In: Nishino, M. (eds) Therapy Response Imaging in Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-030-31171-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31171-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31170-4

  • Online ISBN: 978-3-030-31171-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation